-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The antithrombotic drug market is making a comeback! Recently, Simcere Pharmaceutical won the first imitation of edoxaban tosylate, and Kelun Pharmaceutical's sulda hepaparanox injection and Tianfang Pharmaceutical's agatriproid injection were approved and regarded as reviewed
.
According to data from Intranet, the sales of terminal antithrombotic drugs in China's public medical institutions in 2022H1 exceeded 16 billion yuan, the product TOP10 clopidogrel topped the list, the exclusive variety of indobufen tablets soared by 122.
30%, and the top five seats of the brand TOP10 were monopolized
by foreign-funded enterprises.
At present, 20 varieties of antithrombotic drugs have been evaluated, and 3 varieties are expected to be included in the eighth batch of collective procurement
.
.
According to data from Intranet, the sales of terminal antithrombotic drugs in China's public medical institutions in 2022H1 exceeded 16 billion yuan, the product TOP10 clopidogrel topped the list, the exclusive variety of indobufen tablets soared by 122.
30%, and the top five seats of the brand TOP10 were monopolized
by foreign-funded enterprises.
At present, 20 varieties of antithrombotic drugs have been evaluated, and 3 varieties are expected to be included in the eighth batch of collective procurement
.
Antithrombotic TOP10! Star drug sales halved, exclusive varieties soared 122%
Antithrombotic drugs are the main category in the field of cardiovascular and cerebrovascular diseases, and data from Intranet show that the terminal sales scale of antithrombotic drugs in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) in 2021 exceeded 35 billion yuan, a year-on-year increase of 9.
74%; The sales scale in the first half of 2022 exceeded 16 billion yuan, down 4.
13%
from the same period last year.
74%; The sales scale in the first half of 2022 exceeded 16 billion yuan, down 4.
13%
from the same period last year.
Sales of terminal antithrombotic drugs in public medical institutions in China (10,000 yuan)
Source: Intranet terminal competition pattern of public medical institutions in China
Among the TOP10 antithrombotic drug products, four products such as clopidogrel hydrogen sulfate tablets, enoxaparin sodium injection, aspirin enteric-coated tablets, and rivaroxaban tablets have half-year sales of more than 1 billion yuan, and clopidogrel hydrogen sulfate tablets have maintained the position
of "one brother" with sales of more than 2 billion yuan.
It is worth mentioning that enoxaparin sodium injection and aspirin enteric-coated tablets have not yet been included in the collection
.
of "one brother" with sales of more than 2 billion yuan.
It is worth mentioning that enoxaparin sodium injection and aspirin enteric-coated tablets have not yet been included in the collection
.
From the perspective of sales growth rate, 3 products showed negative growth, the sales of rivaroxaban tablets included in the fifth batch of centralized procurement fell by 49.
95%, and low molecular weight heparin calcium injection fell by 14.
11%; 7 products showed positive growth, the sales of exclusive varieties of indobufen tablets soared by 122.
30%, the first batch of clopidogrel tablets of hydrogen sulfate that were hit hard by centralized procurement began to stop falling and rebound, and heparin sodium injection and beprost sodium tablets rose by more than 10%.
95%, and low molecular weight heparin calcium injection fell by 14.
11%; 7 products showed positive growth, the sales of exclusive varieties of indobufen tablets soared by 122.
30%, the first batch of clopidogrel tablets of hydrogen sulfate that were hit hard by centralized procurement began to stop falling and rebound, and heparin sodium injection and beprost sodium tablets rose by more than 10%.
2022H1 Top 10 terminal antithrombotic drug products in public medical institutions in China
Source: Intranet terminal competition pattern of public medical institutions in China
Among the top 10 antithrombotic drug brands, the top five seats are monopolized by foreign-funded enterprises, and Sanofi and Bayer each have 2 brands on the list; Sanofi's clopidogrel hydrogen sulfate tablets and Bayer's aspirin enteric-coated tablets ranked first and second respectively, with sales exceeding 1 billion yuan; In addition to Sanofi's Porivit, Salubris and Lepu Pharmaceutical's clopidogrel tablets of hydrogen sulfate are also on the list; Domestic brands on the list also include Changshan Pharmaceutical's low molecular weight heparin calcium injection, Hangzhou Sino-American Huadong Pharmaceutical's indobufen tablets, and Tide Pharmaceutical's beprost sodium tablets
.
.
2022H1 Top 10 terminal antithrombotic drug brands in China's public medical institutions
Source: Intranet terminal competition pattern of public medical institutions in China
9 antithrombotic drugs have been collected, 10 billion varieties have stopped falling, and 3 varieties of more than 1 billion have been beaten
In the six batches of chemical drugs carried out by the state, 1, 0, 2, 2, 2, 2 and 3 varieties of antithrombotic drugs were included in the centralized procurement, of which the specifications of ticagrelor oral regular-release dosage form 90mg and 60mg were included in the third and fourth batches of centralized procurement, respectively, so there are a total of 9 varieties
of antithrombotic drugs that have been collected.
of antithrombotic drugs that have been collected.
National collection of antithrombotic drugs
Among the nine varieties, bivalirudin for injection is the first antithrombotic injection included in the collection
.
The antithrombotic drugs included in the seventh batch of centralized procurement are all injections, including fondaparinux injection, tirofiban injection, and etifibatide injection
.
It is worth paying attention to
whether the next batch of centralized procurement will include heparin preparations.
.
The antithrombotic drugs included in the seventh batch of centralized procurement are all injections, including fondaparinux injection, tirofiban injection, and etifibatide injection
.
It is worth paying attention to
whether the next batch of centralized procurement will include heparin preparations.
As a star variety in the antithrombotic drug market, clopidogrel ushered in its peak moment in 2018, with terminal sales of public medical institutions in China exceeding 12 billion yuan, and it was also in this year that clopidogrel oral regular-release dosage forms were first included in the first batch of centralized procurement
.
With the implementation of the 4+7 pilot and expansion in 2019, clopidogrel suffered Waterloo, and sales from 2019 to 2021 fell by 6.
27%, 59.
19% and 3.
11%
year-on-year, respectively.
In 2021, the sales of this product exceeded 4.
5 billion yuan, and in the first half of 2022, sales exceeded 2 billion yuan, a year-on-year increase of 8.
85%, and the annual sales are expected to achieve positive growth
.
.
With the implementation of the 4+7 pilot and expansion in 2019, clopidogrel suffered Waterloo, and sales from 2019 to 2021 fell by 6.
27%, 59.
19% and 3.
11%
year-on-year, respectively.
In 2021, the sales of this product exceeded 4.
5 billion yuan, and in the first half of 2022, sales exceeded 2 billion yuan, a year-on-year increase of 8.
85%, and the annual sales are expected to achieve positive growth
.
Sales of clopidogrel terminals in public medical institutions in China (10,000 yuan)
Source: Intranet terminal competition pattern of public medical institutions in China
Apixaban was first approved for listing in China in 2013, the early market sales have been dismal, in 2017 into the national medical insurance directory ushered in a rapid volume, in 2019 Hausen Pharmaceutical won the first domestic imitation of apixaban tablets, in 2020 the variety was included in the third batch of centralized procurement
.
As a result, apixaban began to decline
in 2020 after the terminal sales scale of China's public medical institutions exceeded 100 million yuan.
.
As a result, apixaban began to decline
in 2020 after the terminal sales scale of China's public medical institutions exceeded 100 million yuan.
Sales of apixaban terminal in China's public medical institutions (10,000 yuan)
Source: Intranet terminal competition pattern of public medical institutions in China
Ticagrelor is a new potent P2Y12 receptor antagonist that was once highly anticipated
by AstraZeneca.
In 2018, the terminal sales of this variety in China's public medical institutions exceeded 1 billion yuan for the first time, and the sales volume in 2020 was close to 1.
7 billion yuan
.
I thought I could take over clopidogrel, but unexpectedly it was a "difficult brother and brother", with the implementation of the third and fourth batches of centralized procurement, the sales of ticagrelor fell by 52.
85%
in 2021.
by AstraZeneca.
In 2018, the terminal sales of this variety in China's public medical institutions exceeded 1 billion yuan for the first time, and the sales volume in 2020 was close to 1.
7 billion yuan
.
I thought I could take over clopidogrel, but unexpectedly it was a "difficult brother and brother", with the implementation of the third and fourth batches of centralized procurement, the sales of ticagrelor fell by 52.
85%
in 2021.
Sales of telagrelor terminals in public medical institutions in China (10,000 yuan)
Source: Intranet terminal competition pattern of public medical institutions in China
Dabigatran etexilate and rivaroxaban were included in the fifth batch of centralized production at the
same time, and the implementation time was October 2021.
In recent years, the terminal sales of these two varieties in China's public medical institutions have continued to grow rapidly, and in 2021, the sales of dabigatran etexilate exceeded 1 billion yuan for the first time, and the sales of rivaroxaban exceeded 4 billion yuan, closely following clopidogrel
.
With the implementation of centralized mining, the sales of dabigatran etexilate and rivaroxaban fell by 38.
19% and 49.
95% respectively in the first half of
2022.
same time, and the implementation time was October 2021.
In recent years, the terminal sales of these two varieties in China's public medical institutions have continued to grow rapidly, and in 2021, the sales of dabigatran etexilate exceeded 1 billion yuan for the first time, and the sales of rivaroxaban exceeded 4 billion yuan, closely following clopidogrel
.
With the implementation of centralized mining, the sales of dabigatran etexilate and rivaroxaban fell by 38.
19% and 49.
95% respectively in the first half of
2022.
Yangtze River, Shi Yao, Qilu.
.
.
20 varieties have been evaluated, and 3 varieties are ready for the eighth batch of collective procurement
.
.
20 varieties have been evaluated, and 3 varieties are ready for the eighth batch of collective procurement
Up to now, 20 varieties of antithrombotic drugs have passed or are deemed to have passed the consistency evaluation
.
Among them, Yangtze River Pharmaceutical Co.
, Ltd.
has 7 varieties evaluated, CSPC Group has 6 varieties have been evaluated, Qilu Pharmaceutical has 5 varieties have been evaluated, and 6 enterprises such as Chia Tai Tianqing, Nanjing Chia Tai Tianqing, Salubris, Beite Pharmaceutical, Lepu Pharmaceutical, Shanghai Pharmaceutical and other 6 enterprises have each had 4 varieties evaluated
.
.
Among them, Yangtze River Pharmaceutical Co.
, Ltd.
has 7 varieties evaluated, CSPC Group has 6 varieties have been evaluated, Qilu Pharmaceutical has 5 varieties have been evaluated, and 6 enterprises such as Chia Tai Tianqing, Nanjing Chia Tai Tianqing, Salubris, Beite Pharmaceutical, Lepu Pharmaceutical, Shanghai Pharmaceutical and other 6 enterprises have each had 4 varieties evaluated
.
Antithrombotic drugs have been evaluated
From the perspective of competition pattern, 5 varieties are the most fiercely competitive, of which as many as 32 companies have been evaluated by rivaroxaban tablets, ticagrelor tablets and apixaban tablets have been evaluated by 27 enterprises each, clopidogrel hydrogen sulfate tablets and tirofiban hydrochloride sodium chloride injection have been evaluated
by 15 and 11 respectively.
by 15 and 11 respectively.
Five varieties are exclusively evaluated, including Sincere Pharmaceutical's edoxaban tosylate tablets, Lunan Bet's tirofiban hydrochloride concentrated solution for injection, Changshan Pharmaceutical's daloxaparin sodium injection, CSPC Group's dipyridamole tablets, and Dongcheng Pharmaceutical's sodium dradularin calcium
for injection.
for injection.
In addition to the varieties that have been included in the national centralized procurement, 3 varieties of antithrombotic drugs have met the national centralized procurement conditions (4 evaluated / 3 evaluated + original research), namely enoxaparin injection, agatroban injection, and nadroheparin calcium injection
.
.
Antithrombotic drugs that are not included in centralized procurement and meet the conditions of 4 companies are currently included
Enoxaparin injection and nadraparin calcium injection are both heparin drugs, and the terminal sales scale of public medical institutions in China will exceed 2.
8 billion yuan and 2.
7 billion yuan respectively in 2021, and the sales scale of agatroban injection will exceed 700 million yuan
.
The possibility of the three varieties being included in the new batch of collective procurement is high, and the relevant unevaluated enterprises need to speed up the progress of
consistency evaluation.
8 billion yuan and 2.
7 billion yuan respectively in 2021, and the sales scale of agatroban injection will exceed 700 million yuan
.
The possibility of the three varieties being included in the new batch of collective procurement is high, and the relevant unevaluated enterprises need to speed up the progress of
consistency evaluation.
Source: Intranet database, company announcement, etc.
Note: Intranet "Terminal Competition Pattern of China's Public Medical Institutions", the statistical scope is: China's urban public hospitals, county-level public hospitals, urban community centers and township health centers, excluding private hospitals, private clinics, village clinics; The above sales are calculated
based on the average retail price of the product at the terminal.
Data statistics as of October 13, if there are any omissions, welcome to correct!
Note: Intranet "Terminal Competition Pattern of China's Public Medical Institutions", the statistical scope is: China's urban public hospitals, county-level public hospitals, urban community centers and township health centers, excluding private hospitals, private clinics, village clinics; The above sales are calculated
based on the average retail price of the product at the terminal.
Data statistics as of October 13, if there are any omissions, welcome to correct!
